Literature DB >> 8318424

Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.

W Scheithauer1, T Schenk, M Czejka.   

Abstract

The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distribution of epirubicin from the serum and altered disposition might, in fact, explain the increased level of myelotoxicity in this pilot as well as in other clinical phase II studies involving DVPM.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8318424      PMCID： PMC1968306          DOI： 10.1038/bjc.1993.277

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  9 in total

1.  High-performance liquid chromatographic determination of adriblastin in human plasma, urine, saliva and liver punctuate by column switching for drug monitoring studies.

Authors:  M J Czejka; A Georgopoulos
Journal:  J Chromatogr       Date:  1988-01-22

Review 2.  Multiple-drug resistance in human cancer.

Authors:  I Pastan; M Gottesman
Journal:  N Engl J Med       Date:  1987-05-28       Impact factor: 91.245

3.  The effect of verapamil on the pharmacokinetics of adriamycin.

Authors:  D J Kerr; J Graham; J Cummings; J G Morrison; G G Thompson; M J Brodie; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.

Authors:  M Eichelbaum; G Mikus; B Vogelgesang
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

5.  Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique.

Authors:  B Vogelgesang; H Echizen; E Schmidt; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

6.  The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans.

Authors:  H Echizen; T Brecht; S Niedergesäss; B Vogelgesang; M Eichelbaum
Journal:  Am Heart J       Date:  1985-02       Impact factor: 4.749

7.  The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific.

Authors:  J A Plumb; R Milroy; S B Kaye
Journal:  Biochem Pharmacol       Date:  1990-02-15       Impact factor: 5.858

8.  Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil.

Authors:  S Merry; P Flanigan; E Schlick; R I Freshney; S B Kaye
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

9.  Phase I and pharmacokinetic study of D-verapamil and doxorubicin.

Authors:  D Bissett; D J Kerr; J Cassidy; P Meredith; U Traugott; S B Kaye
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640
  9 in total
  8 in total

1.  Dexverapamil to overcome epirubicin resistance in advanced breast cancer.

Authors:  B Thürlimann; N Kröger; J Greiner; K Mross; J Schüller; E Schernhammer; K Schumacher; G Gastl; J Hartlapp; H Kupper
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.

Authors:  W Scheithauer; G Kornek; M Raderer; K Koperna-Mach; C Müller; J Karner; J Kastner; C Tetzner
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 3.  Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?

Authors:  G-T Ho; F M Moodie; J Satsangi
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 4.  Pharmacokinetic drug interactions with anticancer drugs.

Authors:  P M Loadman; M C Bibby
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of epirubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

6.  In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation.

Authors:  O Bruserud; I Nesthus; G Pawelec
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

Authors:  M Lehnert; K Mross; J Schueller; B Thuerlimann; N Kroeger; H Kupper
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

8.  Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Authors:  C J Punt; E E Voest; E Tueni; A T Van Oosterom; A Backx; P H De Mulder; B Hecquet; C Lucas; B Gerard; H Bleiberg
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.